For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
the ONA take:
According to a new study published in the journal Science Signaling, a team of researchers from around the world has demonstrated that more than 80% of colorectal cancers could be treated with Janus kinase (JAK) inhibitors. For the study, researchers tested JAK inhibitors in preclinical models of colorectal cancer and human colorectal cancer cells that have elevated levels of Wnt signaling.
A genetic mutation triggers increases levels Wnt pathway signaling, which in turn triggers more than 80% of colorectal cancers. According to the researchers, targeting the Wnt signaling pathway is difficult because normal cells in the intestine require low levels of Wnt signaling to maintain the healthiness of the gut.
The researchers sought to determine whether another signaling pathway, which involves JAK proteins, could be targeted to decrease tumor growth without harming the normal cells of the intestine. They found that inhibiting JAKs could halt cancer growth and no adverse effects were observed in the preclinical models; however, JAK inhibitors were only effective when the colorectal tumors were triggered by defective Wnt signaling, which is about 80-90% of colorectal cancers.
There are currently no JAK inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer.
More than 80% of colorectal cancers could be treated with Janus kinase inhibitors
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|